Changes in Hong Kong stocks | Nuochengjianhua (09969) rose more than 4% in the first half of the year, core products drove growth and accelerated multiple phase III clinical trials

The Zhitong Finance App learned that Nuocheng Jianhua (09969) rose more than 4%. As of press release, it had risen 4.1% to HK$18.01, with a turnover of HK$59.71 million.

According to the news, recently, Nuochengjianhua disclosed its interim results report for the first half of 2025. According to CITIC Construction Investment, the company achieved operating revenue of 74.3 million yuan in 2025H1, an increase of 74.3% over the previous year, mainly due to the continued release of the core product obutinib and the initial payment obtained by the company and the licensing agreement with Prolium. Sales of the core product obutinib reached 637 million yuan, an increase of 52.8% over the previous year. Net profit loss to mother narrowed to -82 million yuan, a year-on-year decrease of 67.4%, mainly due to increased operating income and further improvement in cost efficiency. As of 2025H1, cash and financial assets reached $7.68 billion, providing sufficient guarantees for subsequent R&D and commercialization.

According to the report, Nuochengjianhua is continuing to strengthen its drug discovery platform, focusing on B-cell and T-cell signaling pathways, and is committed to developing cutting-edge global targets in the field of autoimmune diseases and building an autoimmune pipeline with differentiated advantages. The goal is to provide “first-in-class” or “best-in-class” therapies for disease fields with a large number of unmet needs. These innovative drugs have broad application prospects in the global market. Accelerate a number of self-exemption phase III clinical trials to create a second growth curve: the phase III clinical trial of obutinib combined with ICP-248 to treat 1L CLL/SLL-FDT completed enrollment; obutinib completed phase III clinical trials for ITP indications in the field of self-immunity.